Skip to main content
Article thumbnail
Location of Repository

Do New Drugs Increase Life Expectancy? A Critique of a Manhattan Institute Paper

By Dean Baker and Adriane Fugh-Berman

Abstract

A recent study published by the Manhattan Institute “Why Has Longevity Increased More in Some States than in Others? The Role of Medical Innovation and Other Factors,” purported to show that the more rapid adoption of new drugs has substantial benefits in the form of increased life expectancy, higher productivity and lower non-drug health care expenditures. This study has been cited as evidence supporting the more rapid acceptance of new drugs in Medicaid, Medicare, and other public programs and has helped to shape public debate on the value of new drugs. This analysis questions the key conclusions of the study. It points out that the key statistical regressions appear to be misspecified, since they show anomalies such as a negative correlation between income growth and life expectancy and find no relationship between education and productivity growth. Methodological flaws addressed include lack of adjustment for infant mortality rates; inadequate proxy measures of health status; lack of adjustment for ages of individuals and other sociodemographic factors; inherent problems with the definition of drug age, or ‘vintage;’ and the failure to consider reverse causation as an obvious explanation for several findings. The Manhattan Institute study does not provide reliable evidence for favoring adoption of newer drugs in either public or private health care programs

Topics: Perspectives
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2669876
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2003). A further study of life expectancy by socioeconomic factors in the National Longitudinal Mortality Study. Ethn Dis.
    2. A new estimate of the welfare loss of excess health insurance.
    3. (2003). age-adjusted death rates, and life expectancy at birth, by race and sex; and infant mortality rates, by race: United States, final
    4. Are novel drugs more risky for patients than less novel drugs?
    5. Are recessions good for your health?
    6. (1996). Are the benefits of newer drugs worth their cost? Evidence from the
    7. (1992). Baseline health, socioeconomic status, and 10-year mortality among older middle-aged Americans: findings from the Health and Retirement Study,
    8. (2002). Benefits and Costs of newer drugs: an update. NBER Working Paper no 8996.
    9. (2007). CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry.
    10. CATIE Investigators. Effects of antipsychotic medications on psychosocialfunctioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    11. (2007). CDER NDAs Approved in Calendar Years 1990–2004 by Therapeutic Potential and Chemical Type,” Washington, D.C.: Food and Drug Administration,
    12. (2007). Council of Economic Advisors. Economic Report of the President,
    13. Decennial Life tables for 1989–1991: Trends and Comparisons;1(3).
    14. (2008). Department of Commerce, Bureau of Economic Analysis, National Income and Product Accounts, Table 1.1.3, Line 1. Available via the Internet: http://www.bea.gov/national/nipaweb/SelectTable.asp? Selected = N. Accessed
    15. Do higher drug costs lead to better health?
    16. (2007). Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Affairs.
    17. (2003). Further study of life expectancy by socioeconomic factors in the National Longitudinal Mortality Study. Ethn Dis.
    18. Good times make you sick.
    19. Health insurance and the demand for medical care: evidence from a randomized experiment.
    20. New cardiovascular drugs: patterns of use and association with non-drug health expenditures.
    21. (2008). Office. Issues in Designing a Prescription Drug Benefit for Medicare. Available via the Internet at http://cbo.gov/doc.
    22. (2007). Prescription Drug Trends. Kaiser Family Foundation
    23. (2000). Productivity: A Retrospective.
    24. The anatomy of health insurance.
    25. (2008). The gap gets bigger: changes in mortality and life expectancy, by education, 1981–2000. Health Aff (Millwood).
    26. The incomeassociated burden of disease in the United States. Soc Sci Med.
    27. (2003). The siren call of new drugs. Expert Rev Pharmacoeconomics Outcomes Res.
    28. (2006). The Value of Medicines: Facts and Figures
    29. Timing of new black box warnings and withdrawals for prescription medications.
    30. (2008). Top 10 Products by U.S. Dispensed Prescriptions. Available via the Internet: http://www.imshealth.com/deployedfiles/imshealth/
    31. (1983). Trends in the black-white life expectancy gap in the United States,
    32. (2007). Why HasLongevityIncreasedMoreinSomeStatesthanin Others? The Role of Medical Innovation and Other Factors.”
    33. (1980). Widening socioeconomic inequalities in US life expectancy,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.